A research team led by Dr. Tomas Salaya of Bayer Pharmaceuticals conducted a study (called LEADER-75) that included 141 patients diagnosed or suspected of central nervous system conditions. The group evaluated gadobutrol's performance on measures such as subjective enhancement, border delineation, internal morphology of the lesion, number of lesions, diagnostic, diagnostic performance, reader preference, algorithm of contrast enhancement, and security.

The investigators found that reducing the dose of gadobutrol by 25% (to 0.075 mmol/kg) performs comparably across these measures compared to a standard dose of gadoterate (0.1 mmol/kg) for central nervous system imaging indications.

"Clinically, the results of the LEADER-75 motivate the use of a reduced dose of gadobutrol for the study of pathologies of the CNS, without repercussion in the quality of the image and,

therefore, maintaining optimal efficiency in the diagnostic flow of the patient," Salaya said in a statement.